X4 Pharmaceuticals chairman buys 4,600 shares

Adam R. Craig agreed to disgorge to X4 Pharmaceuticals all profits deemed realized from the transaction under Section 16(b).

Rhea-AI Filing Summary

X4 Pharmaceuticals, Inc. Executive Chairman and director Adam R. Craig directly purchased 4,600 shares of common stock on October 16, 2026, at $2.5834 per share. His reported direct position after the purchase was 333,251 shares; of the reported common-stock position, 193,254 shares represent restricted stock units. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Buyer: 4,600 shares

Net Buy 1 txn

Insider Craig Adam R

Role Executive Chairman

Bought 4,600 shs ($12K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2	4,600	$2.5834	$12K

Holdings After Transaction: Common Stock — 333,251 shares (Direct)

Footnotes (2)

1. F1. Of the shares of common stock reported, 193,254 shares represent restricted stock units.
2. F2. The Reporting Person has agreed to disgorge to the Issuer all profits deemed to be realized from this transaction pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.

Key Figures

Shares purchased: 4,600 shares Purchase price: $2.5834 per share Direct shares after purchase: 333,251 shares +1 more

4 metrics

Shares purchased 4,600 shares October 16, 2026

Purchase price $2.5834 per share October 16, 2026

Direct shares after purchase 333,251 shares Reported following the October 16, 2026 purchase

Restricted stock units 193,254 shares Of the reported common-stock position

Key Terms

restricted stock units, disgorge, Section 16(b)

3 terms

restricted stock units financial

"193,254 shares represent restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

disgorge regulatory

"agreed to disgorge to the Issuer all profits"

Section 16(b) regulatory

"pursuant to Section 16(b) of the Securities Exchange Act of 1934"

A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did XFOR executive chairman Adam R. Craig buy?

Adam R. Craig, X4 Pharmaceuticals' Executive Chairman and director, purchased 4,600 shares of common stock on October 16, 2026, at $2.5834 per share. The purchase was direct, and no Rule 10b5-1 plan is reported.

What did Adam R. Craig agree to disgorge to X4 Pharmaceuticals?

He agreed to disgorge to X4 Pharmaceuticals all profits deemed to be realized from the transaction pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 04:06 PM EDT Accepted by SEC EDGAR 10/19/2026 - 04:06 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Craig Adam R

(Last) (First) (Middle)

C/O X4 PHARMACEUTICALS INC.

61 NORTH BEACON STREET, 4TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02134

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
X4 Pharmaceuticals, Inc [ XFOR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/16/2026		P		4,600	A	$2.5834	333,251(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Of the shares of common stock reported, 193,254 shares represent restricted stock units.

2. The Reporting Person has agreed to disgorge to the Issuer all profits deemed to be realized from this transaction pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.

Remarks:

	/s/ David Kirske, Attorney-In-Fact	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)